2-Pentoxypyridine | 1255926-31-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Pentoxypyridine
• CAS: 1255926-31-8
• 化学式: C₁₀H₁₅NO
• mdl: MFCD28168470
• 分子量: 165.235
• InChiKey: JLYXSFWSDGYVFW-UHFFFAOYSA-N

物化性质

• 沸点：
  227.6±13.0 °C(Predicted)
• 密度：
  0.956±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-碘戊烷 、 2-Pentoxypyridine 反应 0.08h， 以75%的产率得到1-pentylpyridin-2(1H)-one
  参考文献：
  名称：

  Microwave Assisted Rapid Preparation of N-Alkyl-2-pyridones under Neutral Conditions by Hilbert-Johnson Reaction

  摘要：

  The reactions of 2-methoxypyridine with haloalkanes without solvent and catalyst under microwave irradiation (100-200 degrees C, 5 min) yielded the corresponding N-alkyl-2(1H)-pyridones in good to moderate yields. However, the reactions were sensitive to length of haloalkanes. In contrast, the reactions of 2-alkoxypyridines with corresponding iodoalkanes under microwave irradiation (150 degrees C) proceeded rapidly without catalyst and solvent, and were complete within 5 min to afford N-alkyl-2(1H)-pyridones in good to excellent yields.

  DOI：

  10.3987/com-10-12006
• 作为产物：
  描述：

  2-溴吡啶 、 戊醇 在 sodium hydride 作用下， 生成 2-Pentoxypyridine
  参考文献：
  名称：

  Microwave Assisted Rapid Preparation of N-Alkyl-2-pyridones under Neutral Conditions by Hilbert-Johnson Reaction

  摘要：

  The reactions of 2-methoxypyridine with haloalkanes without solvent and catalyst under microwave irradiation (100-200 degrees C, 5 min) yielded the corresponding N-alkyl-2(1H)-pyridones in good to moderate yields. However, the reactions were sensitive to length of haloalkanes. In contrast, the reactions of 2-alkoxypyridines with corresponding iodoalkanes under microwave irradiation (150 degrees C) proceeded rapidly without catalyst and solvent, and were complete within 5 min to afford N-alkyl-2(1H)-pyridones in good to excellent yields.

  DOI：

  10.3987/com-10-12006

文献信息

• [EN] ESTER DERIVATIVES OF (PYRIDINYLOXY-PHENYL)-METHANOL AND PROCESS OF PREPARATION THEREOF<br/>[FR] DERIVES ESTERS DE (PYRIDINYLOXY-PHENYL)-METHANOL ET LEUR PROCEDE DE PREPARATION
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2004087667A1

  公开（公告）日：2004-10-14

  The present invention relates to novel pyridinyloxy phenyl methanol derivatives of the formula (III) with X=(a) or (b), obtained by the reaction of 4-/3-(3,5,6-pyridinyl-2-oxy)phenylmethanol and 4-/3-(2,3,5,6-pyridinyl-4-oxy)phenyl methanol with the acid chloride.

  本发明涉及具有以下结构的新型吡啶氧基苯甲醇衍生物（III）：X =（a）或（b），通过4-/3-(3,5,6-吡啶基-2-氧基)苯甲醇和4-/3-(2,3,5,6-吡啶基-4-氧基)苯甲醇与酸氯反应而得到。
• Human adam-10 inhibitors
  申请人：Brown David S.

  公开号：US20050227973A1

  公开（公告）日：2005-10-13

  The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chorides and ADAM-10 modulators therefrom.

  本发明提供了用于抑制ADAM-10蛋白质的化合物。这些化合物在体外研究ADAM-10（及其抑制）在生物过程中的作用方面非常有用。本发明还包括药物组合物，其包括根据本发明的一种或多种ADAM-10抑制剂和药学上可接受的载体。这些组合物对于治疗癌症、关节炎和与血管生成相关的疾病非常有用。相应地，本发明还包括治疗癌症、关节炎和与血管生成相关的疾病的方法，其中ADAM-10发挥关键作用。本发明还提供了制备双芳基醚磺酰氯和ADAM-10调节剂的方法。
• Crf Receptor Antagonists and Methods Relating Thereto
  申请人：Luo Zhiyong

  公开号：US20070287705A1

  公开（公告）日：2007-12-13

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了CRF受体拮抗剂，其在治疗各种疾病中具有用途，包括治疗温血动物中CRF分泌过多表现的疾病，例如中风。本发明的CRF受体拮抗剂具有以下结构（I），包括立体异构体、前药和其药物可接受的盐，其中R1、R2、R3、Y、Ar和het的定义如下。本发明还揭示了含有CRF受体拮抗剂和药物可接受载体的组合物，以及使用它们的方法。
• N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS
  申请人：Kurimura Muneaki

  公开号：US20090088406A1

  公开（公告）日：2009-04-02

  The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R 101 and R 102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

  本发明提供了一种吡咯烷化合物，其一般式为（1），或其盐，其中R101和R102分别是苯基或吡啶基，苯基或吡啶基可以具有一个或多个卤原子和低碳基团，可选地取代一个或多个卤原子等。本发明的吡咯烷化合物或其盐可用于制备具有更广泛治疗谱并能够在短期内展现足够治疗效果的药物制剂。
• N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS
  申请人：KURIMURA Muneaki

  公开号：US20120065162A1

  公开（公告）日：2012-03-15

  The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R 101 and R 102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

  本发明提供了一种吡咯烷化合物通式（1）或其盐，其中R101和R102各自独立地为苯基或吡啶基，所述苯基或吡啶基可以具有一个或多个卤素原子和低碳基团中的一个或多个卤素原子等取代基。本发明的吡咯烷化合物或其盐可用于制备具有更广泛治疗谱并能够在短期内展现足够治疗效果的药物制剂。